Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
ATROVENT HFA |
| Manufacturer |
|
Boehringer Ingelheim Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Anticholinergic. |
| Generic Name |
|
Ipratropium bromide 17micrograms/inh; metered dose inhaler; CFC-free. |
| Also |
|
• ATROVENT INH SOLN
|
| Indications |
|
Bronchospasm associated with chronic bronchitis and emphysema. |
| Children |
|
Not recommended. |
| Adults |
|
2 inh 4 times daily; max 12 inh/day. |
| Contraindications |
|
Allergy to atropine or its derivatives. Atrovent Inhaler, but not Atrovent HFA inhaler: allergy to soya lecithin, peanut, or related foods. |
| Precautions |
|
Not for primary treatment of acute attack. Avoid eyes. Narrow-angle glaucoma. GI or GU obstruction. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Caution with other anticholinergics. |
| Adverse Reactions |
|
Exacerbation of symptoms, cough, nervousness, dizziness, GI upset, headache, palpitations, local irritation, anticholinergic effects, rash. |
| How Supplied |
Inhaler—12.9g (200 inh)
Soln (2.5mL/vial)—25 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
